Related Experiment Video
Updated: May 6, 2026

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Nafamostat Mesylate for the Hypercoagulable State of SARS-CoV-2 With Renal Replacement Therapy: A Case Report
Koki Nakada1, Daisuke Hirai2, Koichi Seta2
1Emergency Department, Kyoto Prefectural University of Medicine, Kyoto, JPN.
Abstract:
Being a dialysis patient is one of the risks for severe coronavirus disease 2019 (COVID-19) cases. In addition, there have been many reports of coagulation abnormalities in severe COVID-19 cases; these also make dialysis management more difficult. In this study, we report a case of severe COVID-19 in a hemodialysis patient who had coagulation in the dialysis circuit with unfractionated heparin (UFH), which could be managed without intracircuit obstruction when nafamostat mesylate (NM) was used in combination with unfractionated heparin.
More Related Videos
Related Concept Videos
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Nephrotic Syndrome II : Assessment and Medical Management
Continuous Renal Replacement Therapy
Hemodialysis II: Procedure and Complications
Acute Kidney Injury IV: Diagnostic Studies and Prevention

